Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03805438 · ClinicalTrials.gov registry record · Phase 4

ED90 of 3% Chloroprocaine for Cervical Cerclage

A Phase 4 study of Cerclage, Cervical, sponsored by Duke University.

Completed
Registry status
Phase 4
Development phase
47
Enrollment target
2
Study locations

NCT03805438 is a Phase 4 study of Cerclage, Cervical that has completed, run by Duke University. The registered enrollment target is 47 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03805438, a Phase 4 study of Cerclage, Cervical, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 4
Development phase
47 participants
Enrollment target
2
Study locations

Study Summary

The aim of this study is to identify the dose of intrathecal (IT) chloroprocaine that provides effective anesthesia in 90% of patients undergoing elective cerclage placement (intraoperative analgesic supplementation not required).

Conditions Studied

Interventions

  • DRUG Chloroprocaine Hcl 3% Inj

Study Locations (2)

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

North Carolina

  • Duke University Hospital - Durham

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2019-02-07
Est. Completion 2020-10-23
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT03805438

The ClinicalTrials.gov registry entry for NCT03805438 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cerclage, Cervical appearing as the primary indexed condition, and to 1 intervention - of which Chloroprocaine Hcl 3% Inj is the first listed.

NCT03805438 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arkansas, North Carolina.

Frequently Asked Questions

What is clinical trial NCT03805438 about?

NCT03805438 is a clinical study titled "ED90 of 3% Chloroprocaine for Cervical Cerclage". The aim of this study is to identify the dose of intrathecal (IT) chloroprocaine that provides effective anesthesia in 90% of patients undergoing elective cerclage placement (intraoperative analgesic supplementation not required).

What is the current status of trial NCT03805438?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2019-02-07. Estimated completion is 2020-10-23.

What conditions does trial NCT03805438 study?

This clinical trial studies the following conditions: Cerclage, Cervical.

What interventions are being tested in trial NCT03805438?

The interventions under investigation include: Chloroprocaine Hcl 3% Inj (DRUG).

Who is sponsoring clinical trial NCT03805438?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03805438 being conducted?

This trial has 2 study locations across Arkansas, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.